Aug 2026
Model-informed dose optimization of etrasimod in ulcerative colitis across CYP2C9 genotypes and hepatic impairment.
In Chinese populations, hepatic impairment and CYP2C9 polymorphisms increased etrasimod exposure, with the greatest increase observed in CYP2C9 poor metabolizers with Child-Pugh C hepatic impairment (67% increase in AUCss).
Zi-Han Xu, Fangyi Qian, Yi-Ke Liu et al.
· British Journal of Clinical... · 0 citations